Terapia gênica no avanço do tratamento da ataxia espinocerebelar
Gene therapy in advancing the treatment of spinocerebellar ataxia
DOI:
https://doi.org/10.34117/bjdv8n12-097Keywords:
terapia gênica, sistema nervoso, doenças neurodegenerativas, ataxia espinocerebelar, trinucleotídeosAbstract
Objetivo-. Este trabalho teve como objetivo apresentar os avanços da terapia gênica na ataxia cerebelar, com ênfase na área espinocerebelar. Métodos - Foram coletadas informações de artigos originais, publicados em revistas, nos idiomas, inglês, português e espanhol, as bases de busca foram a Biblioteca Virtual em Saúde (BVS), Scientific Electronic Library Online (SciELO), Google Acadêmico e no site do National Center for Biotechnology Information (NCBI), com prioridade de artigos dos últimos dez anos. Resultados- Foi demonstrado que o modelo de tratamento de ataxias espinocerebelares por meio de vírus associados a adeno (AAV) junto a um RNA é uma técnica com potencial, capaz de retardar e reverter os sintomas da doença, porém ainda não se tem comprovação de segurança, devido ao pouco conhecimento sobre o assunto(excluir pois não podemos desmerecer a técnica). Conclusão – Como abordado nesse trabalho, A terapia gênica tem se mostrado a forma mais adequada de tratamento de ataxias espinocerebelares que causam poliglutaminas, por este fato se faz necessário mais pesquisas a respeito.
References
ALONSO, I.; BARROS, J.; TUNA, A.; et al. Phenotypes of Spinocerebellar Ataxia Type 6 and Familial Hemiplegic Migraine Caused by a Unique CACNA1A Missense Mutation in Patients From a Large Family. Archives of Neurology, v. 60, n. 4, p. 610–4, 2003. https://pubmed.ncbi.nlm.nih.gov/12707077/
ASHIZAWA, T.; ÖZ, G.; PAULSON, H. L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nature Reviews Neurology, v. 14, n. 10, p. 590–605, 2018. https://pubmed.ncbi.nlm.nih.gov/30131520/
BIRD, T. D. Hereditary Ataxia Overview. Gene Reviews, v. s/v, n. s/n, p. 1–39, 2019. https://www.ncbi.nlm.nih.gov/books/NBK1138/
BOUDREAU, R. L.; MARTINS, I.; DAVIDSON, B. L. Artificial MicroRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and In vivo. Molecular Therapy, v. 17, n. 1, p. 169–75, 2009. https://pubmed.ncbi.nlm.nih.gov/19002161/
CARRELL, E. M.; KEISER, M. S.; ROBBINS, A. B.; DAVIDSON, B. L. Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice. Molecular Therapy - Methods and Clinical Development, v. 25, n. s/n, p. 333–43, 2022. https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(22)00052-3
CENDELIN, J.; CVETANOVIC, M.; GANDELMAN, M.; et al. Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications. Cerebellum, v. 21, n. 3, p. 452–81, 2022. https://pubmed.ncbi.nlm.nih.gov/34378174/
CENDES, I. L. Expansão de poliglutaminas e doenças neurodegenerativas. Ciência e Cultura, v. 56, n. 1, p. 27–8, 2004. http://cienciaecultura.bvs.br/scielo.php?script=sci_arttext&pid=S0009-67252004000100021 - :~:text=Existem%20muitas%20evid%C3%AAncias%20sugerindo%20um,expandidos(15%2C16).
CHAN, K. Y.; JANG, M. J.; YOO, B. B.; et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nature Neuroscience, v. 20, n. 8, p. 1–27, 2017. https://pubmed.ncbi.nlm.nih.gov/28671695/
CHILDS, B.; VALLE, D. Genetics, Biology and Disease. Annual Reviews, v. 1, n. s/n, p. 1–9, 2000. https://pubmed.ncbi.nlm.nih.gov/11701622/
COSTANZI-STRAUSS, E.; STRAUSS, B. E. Perspectivas da terapia gênica. Revista de Medicina, v. 94, n. 4, p. 211–22, 2015. https://www.revistas.usp.br/revistadc/article/view/108767
CUMMINGS, C. J.; ZOGHBI, H. Y. Trinucleotide repeats: Mechanisms and Pathophysiology. Annual Reviews, v. 1, n. 1, p. 281–328, 2000. https://pubmed.ncbi.nlm.nih.gov/11701632/
FARUQ, M.; SRIVASTAVA, A. K.; SINGH, S.; et al. Spinocerebellar ataxia 7 (SCA7) in Indian population: Predilection of ATXN7-CAG expansion mutation in an ethnic population. Indian Journal of Medical Research, v. 142, n. s/n, p. 187–98, 2015. https://pubmed.ncbi.nlm.nih.gov/25900954/
GENNARINO, V. A.; PALMER, E. E.; MCDONELL, L. M.; et al. A mild PUM1 mutation is associated with adult-onset ataxia, whereas haploinsufficiency causes developmental delay and seizures. Cell, v. 172, n. 5, p. 924–36, 2019. https://pubmed.ncbi.nlm.nih.gov/29474920/
GIL, A. C. Como elaborar projetos de pesquisa. 3rd ed. São Paulo: Atlas, 2002. https://docente.ifrn.edu.br/mauriciofacanha/ensino-superior/redacao-cientifica/livros/gil-a.-c.-como-elaborar-projetos-de-pesquisa.-sao-paulo-atlas-2002./view
GONDIN, F.; THOMAS, F.; GRAÇA, J.; MARTINEZ, A.; FRANÇA, M. Comprometimento medular em doenças neurodegenerativas. Lesões Medulares Clínicas e Experimentais. 1st ed., v. 21, p.360p, 2016. Fortaleza: Imprensa Universitária. https://scholar.google.com.br/scholar?q=Comprometimento+medular+em+doen%C3%A7as+neurodegenerativas&hl=pt-BR&as_sdt=0&as_vis=1&oi=scholart
HOLMES, S. E.; O’HEARN, E.; MARGOLIS, R. L. Why is SCA12 different from other SCAs? Cytogenetic and Genome Research, v. 100, n. 1–4, p. 189–97, 2003. https://pubmed.ncbi.nlm.nih.gov/14526180/ - :~:text=Spinocerebellar%20ataxia%20type%2012%20(SCA12,with%20variability%20in%20other%20signs.
JANSEN-WEST, K.; TODD, T. W.; DAUGHRITY, L. M.; et al. Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model. Frontiers in Cell and Developmental Biology, v. 10, n. s/n, p. 1–4, 2022. https://pubmed.ncbi.nlm.nih.gov/35386195/
KEISER, M. S.; KORDOWER, J. H.; GONZALEZ-ALEGRE, P.; DAVIDSON, B. L. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain, v. 138, n. 12, p. 3555–66, 2015. https://pubmed.ncbi.nlm.nih.gov/26490326/
KEISER, M. S.; MONTEYS, A. M.; CORBAU, R.; GONZALEZ-ALEGRE, P.; DAVIDSON, B. L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Annals of Neurology, v. 80, n. 5, p. 754–65, 2016. https://pubmed.ncbi.nlm.nih.gov/27686464/
KEISER, M. S.; RANUM, P. T.; YRIGOLLEN, C. M.; et al. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain. Nature Medicine, v. 27, n. 11, p. 1982–9, 2021. https://pubmed.ncbi.nlm.nih.gov/34663988/
KOSHY, B.; MATILLA, T.; BURRIGHT, E. N.; et al. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Human Molecular Genetics, v. 5, n. 9, p. 1311–8, 1996. https://pubmed.ncbi.nlm.nih.gov/8872471/
LI, S.; LI, X.-J. Large Animal Models of Huntington’s Disease. Brain Imaging in Behavioral Neuroscience, v. 22, n. s/n, p. 289–320, 2017. https://pubmed.ncbi.nlm.nih.gov/24048953/
MARTIER, R.; SOGORB-GONZALEZ, M.; STRICKER-SHAVER, J.; et al. Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease. Molecular Therapy - Methods and Clinical Development, v. 15, n. s/n, p. 343–58, 2019. https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(19)30116-0
MONIN, M. L.; TEZENAS DU MONTCEL, S.; MARELLI, C.; et al. Survival and severity in dominant cerebellar ataxias. Annals of Clinical and Translational Neurology, v. 2, n. 2, p. 202–7, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338960/
NOBRE, R. J.; LOBO, D. D.; HENRIQUES, C.; et al. miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3. Nucleic Acid Therapeutics, v. 32, n. 3, p. 194–205, 2022. https://pubmed.ncbi.nlm.nih.gov/34878314/
ORENGO, J. P.; NITSCHKE, L.; HEIJDEN, M. E. VAN DER; et al. Reduction of mutant ATXN1 rescues premature death in a conditional SCA1 mouse model. JCI Insight, v. 7, n. 8, p. 1–5, 2022. https://pubmed.ncbi.nlm.nih.gov/35290244/
PACAK, C. A.; SAKAI, Y.; THATTALIYATH, B. D.; MAH, C. S.; BYRNE, B. J. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genetic Vaccines and Therapy, v. 6, p. 1–5, 2008. https://pubmed.ncbi.nlm.nih.gov/18811960/
PRUDENCIO, M.; MORENO-GARCIA, H.; PETRUCELLI, L. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Transl Med, v. 12, n. 566, p. 1–23, 2021. https://pubmed.ncbi.nlm.nih.gov/33087504/
PUHL, D.; AMATO, A.; GILBERT, R. Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bulletin, v. 150, n. s/n, p. 1–39, 2021. https://pubmed.ncbi.nlm.nih.gov/31173859/
PULST, S. M.; NECHIPORUK, A.; NECHIPORUK, T.; et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature genetics, v. 14, n. 3, p. 269–76, 1996. https://pubmed.ncbi.nlm.nih.gov/8896555/
RUANO, L.; MELO, C.; SILVA, M. C.; COUTINHO, P. The global epidemiology of hereditary ataxia and spastic paraplegia: A systematic review of prevalence studies. Neuroepidemiology, v. 42, n. 3, p. 174–83, 2014. https://pubmed.ncbi.nlm.nih.gov/24603320/
SILVA, A. C. R.; BARBOSA, J. J. Realidades e perspectivas do uso de terapia gênica no tratamento de doenças. Revista da Faculdade de Ciências Médicas de Sorocaba, v. 20, n. 3, p. 122–7, 2018. https://revistas.pucsp.br/index.php/RFCMS/article/view/35040
SUN, J.; ROY, S. Gene-based therapies for neurodegenerative diseases. Nature Neuroscience, v. 24, n. 3, p. 297–311, 2021. https://pubmed.ncbi.nlm.nih.gov/33526943/
ZHANG, N.; BEWICK, B.; SCHULTZ, J.; et al. DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases. Neurotherapeutics, v. 18, n. 3, p. 1710–28, 2021. https://pubmed.ncbi.nlm.nih.gov/34160773/
